» Articles » PMID: 35308237

DNA Methylation Aberrant in Atherosclerosis

Overview
Journal Front Pharmacol
Date 2022 Mar 21
PMID 35308237
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis (AS) is a pathological process involving lipid oxidation, immune system activation, and endothelial dysfunction. The activated immune system could lead to inflammation and oxidative stress. Risk factors like aging and hyperhomocysteinemia also promote the progression of AS. Epigenetic modifications, including DNA methylation, histone modification, and non-coding RNA, are involved in the modulation of genes between the environment and AS formation. DNA methylation is one of the most important epigenetic mechanisms in the pathogenesis of AS. However, the relationship between the progression of AS and DNA methylation is not completely understood. This review will discuss the abnormal changes of DNA methylation in AS, including genome-wide hypermethylation dominating in AS with an increase of age, hypermethylation links with methyl supply and generating hyperhomocysteinemia, and the influence of oxidative stress with the demethylation process by interfering with the hydroxyl-methylation of TET proteins. The review will also summarize the current status of epigenetic treatment, which may provide new direction and potential therapeutic targets for AS.

Citing Articles

Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.

Karakasis P, Theofilis P, Patoulias D, Vlachakis P, Antoniadis A, Fragakis N Int J Mol Sci. 2025; 26(5).

PMID: 40076813 PMC: 11900163. DOI: 10.3390/ijms26052196.


Exercise-mediated epigenetic modifications in cardiovascular diseases.

Yang X, Zhang Y, Wang X, Chen S, Zheng Y, Hou X Epigenomics. 2025; 17(3):179-191.

PMID: 39929231 PMC: 11812364. DOI: 10.1080/17501911.2024.2447811.


Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.

Khan A, Jandeleit-Dahm K Nat Rev Cardiol. 2025; .

PMID: 39805949 DOI: 10.1038/s41569-024-01115-w.


High-Fat Diet, Epigenetics, and Atherosclerosis: A Narrative Review.

Rai V Nutrients. 2025; 17(1.

PMID: 39796562 PMC: 11722563. DOI: 10.3390/nu17010127.


Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.

Andersen C, Fernandez M Nutrients. 2025; 17(1.

PMID: 39796476 PMC: 11722654. DOI: 10.3390/nu17010042.


References
1.
Tabaei S, Tabaee S . DNA methylation abnormalities in atherosclerosis. Artif Cells Nanomed Biotechnol. 2019; 47(1):2031-2041. DOI: 10.1080/21691401.2019.1617724. View

2.
Aavik E, Babu M, Yla-Herttuala S . DNA methylation processes in atheosclerotic plaque. Atherosclerosis. 2018; 281:168-179. DOI: 10.1016/j.atherosclerosis.2018.12.006. View

3.
Gujar H, Weisenberger D, Liang G . The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome. Genes (Basel). 2019; 10(2). PMC: 6409524. DOI: 10.3390/genes10020172. View

4.
Lacey M, Baribault C, Ehrlich K, Ehrlich M . Atherosclerosis-associated differentially methylated regions can reflect the disease phenotype and are often at enhancers. Atherosclerosis. 2018; 280:183-191. PMC: 6348116. DOI: 10.1016/j.atherosclerosis.2018.11.031. View

5.
Yuan Y, Xu L, Geng Z, Liu J, Zhang L, Wu Y . The role of non-coding RNA network in atherosclerosis. Life Sci. 2020; 265:118756. DOI: 10.1016/j.lfs.2020.118756. View